ArticleBMC infectious diseases2018
Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016.
Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Preisolation measures and clinical features for pediatric patients with suspicious COVID-19.Health science reports · 2023Article
- Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis.European heart journal. Cardiovascular pharmacotherapy · 2022Article
- SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.Pathogens (Basel, Switzerland) · 2022Review
- 'Convalescent Plasma'- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review.Infectious disorders drug targets · 2022Article
- Clinical, biological and radiological features, 4-week outcomes and prognostic factors in COVID-19 elderly inpatients.Infectious diseases now · 2021Article
- Four Cases of Coronavirus Disease 2019 Transferred from a Cruise Ship.Internal medicine (Tokyo, Japan) · 2021Article
- The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.Virology · 2020Review
- Middle East Respiratory Syndrome (MERS) and novel coronavirus disease-2019 (COVID-19): From causes to preventions in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Review
- Focus on the 2019 novel coronavirus (SARS-CoV-2).Future microbiology · 2020Review
- Emergence of novel coronavirus and progress toward treatment and vaccine.Reviews in medical virology · 2020Review
- Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.AAPS PharmSciTech · 2020Review
- Focus on Middle East respiratory syndrome coronavirus (MERS-CoV).Medecine et maladies infectieuses · 2020Review
- Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review.Annals of translational medicine · 2020Article
- Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks.Frontiers in medicine · 2020Review
- Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2.Frontiers in cell and developmental biology · 2020Review
- What are the drugs having potential against COVID-19?Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2020Review
- The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper.Journal of global infectious diseasesArticle
- Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with suspected Middle East respiratory syndrome coronavirus (MERS-CoV) infection should be hospitalized in isolation wards to avoid transmission. This suspicion can also lead to medical confusion and inappropriate management of acute respiratory syndrome due to causes other than MERS-CoV.
methodsWe studied the characteristics and outcome of patients hospitalized for suspected MERS-CoV infection in the isolation wards of two referral infectious disease departments in the Paris area between January 2013 and December 2016.
resultsOf 93 adult patients (49 male (52.6%), median age 63.4 years) hospitalized, 82 out of 93 adult patients had returned from Saudi Arabia, and 74 of them were pilgrims (Hajj). Chest X-ray findings were abnormal in 72 (77%) patients. The 93 patients were negative for MERS-CoV RT-PCR, and 70 (75.2%) patients had documented infection, 47 (50.5%) viral, 22 (23.6%) bacterial and one Plasmodium falciparum malaria. Microbiological analysis identified Rhinovirus (27.9%), Influenza virus (26.8%), Legionella pneumophila (7.5%), Streptococcus pneumoniae (7.5%), and non-MERS-coronavirus (6.4%). Antibiotics were initiated in 81 (87%) cases, with two antibiotics in 63 patients (67.7%). The median duration of hospitalization and isolation was 3 days (1-33) and 24 h (8-92), respectively. Time of isolation decreased over time (P < 0.01). Two patients (2%) died.
conclusionThe management of patients with possible MERS-CoV infection requires medical facilities with trained personnel, and rapid access to virological results. Empirical treatment with neuraminidase inhibitors and an association of antibiotics effective against S. pneumoniae and L. pneumophila are the cornerstones of the management of patients hospitalized for suspected MERS-CoV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.